AngioDynamics Inc. (ANGO) awards 11,887 RSUs to board director

Rhea-AI Filing Summary

JOHNSON WESLEY reported acquisition or exercise transactions in this Form 4 filing.

AngioDynamics Inc. director Wesley Johnson received a grant of 11,887 shares of common stock in the form of restricted stock units on 2026-07-15 as regular annual compensation for board service. The units immediately vested, bringing his directly held common shares to 155,425.

Insider Trade Summary

Net Buyer: 11,887 shares

Net Buy 1 txn

Insider JOHNSON WESLEY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	11,887	$0.00	$0.00

Holdings After Transaction: Common Stock — 155,425 shares (Direct)

Footnotes (1)

1. F1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

Key Figures

RSUs granted: 11,887 shares Grant price per share: $0.0000 Shares owned after grant: 155,425 shares

3 metrics

RSUs granted 11,887 shares Restricted stock units granted on 2026-07-15 as annual director compensation

Grant price per share $0.0000 Per-share grant price reported for the restricted stock unit award

Shares owned after grant 155,425 shares Total directly held AngioDynamics common shares following the award

Key Terms

restricted stock units, regular annual compensation, immediately vested

3 terms

restricted stock units financial

"represents 11,887 restricted stock units granted as regular annual"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

regular annual compensation financial

"restricted stock units granted as regular annual compensation for service"

immediately vested financial

"The restricted stock units immediately vested at the time of grant"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/22/2026 - 08:06 PM Accepted by SEC EDGAR 07/22/2026 - 08:06 PM Learn about SEC filing dates

FAQ

What insider transaction did AngioDynamics (ANGO) director Wesley Johnson report?

Wesley Johnson reported acquiring 11,887 restricted stock units for AngioDynamics common stock on 2026-07-15. The grant was described as regular annual compensation for his service as a director and immediately vested, increasing his direct holdings to 155,425 shares.

How many AngioDynamics (ANGO) shares does Wesley Johnson own after this Form 4 transaction?

After the reported grant, Wesley Johnson directly owns 155,425 shares of AngioDynamics common stock. This total reflects the addition of 11,887 shares delivered through immediately vested restricted stock units granted as his regular annual director compensation.

What is the nature of the 11,887-share award reported for AngioDynamics (ANGO)?

The 11,887-share award represents restricted stock units granted as regular annual compensation for serving as an AngioDynamics director. According to the disclosure, these restricted stock units immediately vested at the time of grant and convert into an equivalent number of common shares.

Was Wesley Johnson’s AngioDynamics (ANGO) equity award under a Rule 10b5-1 trading plan?

The disclosure’s Rule 10b5-1 checkbox is not marked as an affirming trading plan. The transaction is characterized as a grant of restricted stock units for regular annual director compensation, not as an open-market trade under a pre-arranged trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON WESLEY

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		11,887(1)	A	$0	155,425	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)